
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Opthea Ltd (OPT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: OPT (3-star) is a STRONG-BUY. BUY since 19 days. Profits (14.29%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit 68.35% | Avg. Invested days 35 | Today’s Advisory Regular Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 801.75M USD | Price to earnings Ratio - | 1Y Target Price 12.17 |
Price to earnings Ratio - | 1Y Target Price 12.17 | ||
Volume (30-day avg) 37713 | Beta 1.65 | 52 Weeks Range 1.79 - 6.30 | Updated Date 02/18/2025 |
52 Weeks Range 1.79 - 6.30 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.76 |
Earnings Date
Report Date 2025-02-26 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -164535.56% |
Management Effectiveness
Return on Assets (TTM) -83.43% | Return on Equity (TTM) -3383.08% |
Valuation
Trailing PE - | Forward PE 6.73 | Enterprise Value 758411830 | Price to Sales(TTM) 3061.77 |
Enterprise Value 758411830 | Price to Sales(TTM) 3061.77 | ||
Enterprise Value to Revenue 6083.55 | Enterprise Value to EBITDA -0.73 | Shares Outstanding 153887008 | Shares Floating 785869249 |
Shares Outstanding 153887008 | Shares Floating 785869249 | ||
Percent Insiders - | Percent Institutions 3.5 |
AI Summary
Opthea Ltd. (OPT) Stock Overview:
Company Profile:
History and Background:
Opthea Limited (OPT) is a late-stage biopharmaceutical company established in 2010. The company's headquarters are located in Melbourne, Australia. Opthea focuses on developing novel therapies for eye diseases, particularly those causing vision loss.
Core Business Areas:
Opthea's core business areas revolve around developing and commercializing drugs for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The company's lead product candidate, OPT-302, is a novel anti-VEGF therapy currently in Phase 3 clinical trials for both wet AMD and DME.
Leadership and Corporate Structure:
Opthea operates under a Board of Directors and an executive leadership team. The current CEO is Dr. Megan Baldwin, who has extensive experience in the pharmaceutical industry. The Board consists of experienced individuals with expertise in finance, medicine, business development, and regulatory affairs.
Top Products and Market Share:
Products:
- OPT-302: This anti-VEGF therapy is Opthea's lead product candidate for treating wet AMD and DME. It is designed to offer a longer duration of action compared to existing anti-VEGF treatments.
- OPT-401: This is a second-generation anti-VEGF therapy currently in Phase 1/2a clinical trials for treating wet AMD.
Market Share:
OPT-302 is not yet commercially available, so Opthea does not currently hold any market share. However, the market for wet AMD and DME treatments is significant. In 2022, the global market for these therapies was estimated at approximately $12 billion, with a projected growth to $18 billion by 2027.
Product Performance and Market Reception:
OPT-302 has demonstrated promising results in clinical trials, showing efficacy and safety comparable to existing anti-VEGF therapies. However, the drug's longer duration of action could offer a significant advantage over competitors.
Total Addressable Market (TAM):
The TAM for Opthea's products includes patients with wet AMD and DME globally. The estimated TAM for these indications is approximately 10 million patients.
Financial Performance:
Being a clinical-stage company, Opthea is yet to generate significant revenue. As of June 30, 2023, the company had accumulated a net loss of $262.4 million. However, Opthea has a strong cash position of $175.4 million, which is expected to support its ongoing clinical trials and operations.
Dividends and Shareholder Returns:
Opthea currently does not pay dividends as it is focused on reinvesting its resources into research and development.
Growth Trajectory:
Opthea's growth is highly dependent on the success of its lead product candidate, OPT-302. If approved, this drug could significantly impact the company's financial performance and market position. Additionally, Opthea is actively exploring new product opportunities and potential partnerships to further its growth prospects.
Market Dynamics:
The market for wet AMD and DME treatments is highly competitive, with several established players like Regeneron (REGN), Roche (RHHBY), and Bayer (BAYRY). However, Opthea's differentiated product profile with a longer duration of action positions it favorably within this competitive landscape.
Competitors:
- Regeneron (REGN): Key product - Eylea (anti-VEGF therapy)
- Roche (RHHBY): Key product - Lucentis (anti-VEGF therapy)
- Bayer (BAYRY): Key product - Eylea (marketed in collaboration with Regeneron)
Market Share:
- Regeneron: ~40%
- Roche: ~30%
- Bayer: ~20%
- Opthea: currently 0%
Competitive Advantages:
- Longer duration of action of OPT-302 compared to existing anti-VEGF therapies.
- Potential for reduced treatment burden for patients.
- Strong intellectual property portfolio.
Competitive Disadvantages:
- Limited commercial experience.
- Dependence on the success of OPT-302.
Potential Challenges and Opportunities:
Challenges:
- Competition from established players in the market.
- Regulatory hurdles for product approval.
- Managing research and development costs.
Opportunities:
- Expanding into new geographic markets.
- Developing additional product candidates for other eye diseases.
- Strategic partnerships with other pharmaceutical companies.
Recent Acquisitions:
Opthea has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an analysis of Opthea's financial health, market position, and future prospects, an AI-based rating system could assign a score of 7 out of 10. This rating reflects the company's promising product pipeline, strong cash position, and favorable market dynamics. However, the rating also acknowledges the company's early-stage development and dependence on the success of its lead product candidate.
Sources and Disclaimers:
This analysis used information from Opthea's website, financial reports, investor presentations, and industry reports. Please note that this information is not intended as financial advice, and you should conduct your research before making any investment decisions.
About Opthea Ltd
Exchange NASDAQ | Headquaters South Yarra, VIC, Australia | ||
IPO Launch date 2012-04-12 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://opthea.com |
Full time employees 33 | Website https://opthea.com |
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.